Company Encyclopedia
View More
name
Formycon AG
FYB.DE
News
View More

Formycon AG reports €19.5 million revenue for first nine months of 2025

Formycon AG reported revenues of €19.5 million for the first nine months of 2025, down from €41.1 million in 2024, due to a shift from one-time license payments to sales from commercialized products. The company posted an EBITDA of €-21.7 million and a net result of €-21.4 million. Working capital increased to €83.2 million, aided by a €70 million corporate bond. Formycon confirmed its full-year EBITDA guidance and anticipates a positive EBITDA by 2026 or 2027, with key developments in biosimilars in the US and Europe.

Reuters·
DE
FYB
0.00%
Reuters·
DE
FYB
0.00%

Formycon AG to Release Nine-Month 2025 Results

Formycon AG will release its Nine-Month Results for 2025 on November 13, 2025. A conference call with the Management Board will take place on the same day at 3:00 PM (CET) to discuss the results. The results will be available on the Formycon website, and a live audio webcast will also be accessible. Registration is required for participation.

Reuters·
DE
FYB
0.00%
Reuters·
DE
FYB
0.00%

Formycon AG: Strategic Advancements and Market Opportunities Drive Buy Rating

Yi Chen has assigned a Buy rating to Formycon AG, citing the successful launch of its ranibizumab biosimilar, FYB201, in Europe, which offers advantages like reduced preparation time. Regulatory challenges for competitor Xbrane Biopharma enhance Formycon's position as Sandoz prepares to market FYB201 in the U.S. by mid-2026. A strategic settlement with Regeneron for FYB203 allows for a potential U.S. launch in late 2026. Anticipated results from the Dahlia trial of FYB206 in early 2026 could further strengthen Formycon's growth prospects.

Tip Ranks·
DE
FYB
0.00%
Tip Ranks·
DE
FYB
0.00%

Formycon’s FYB201/Ranivisio® Is Europe’s First Ranibizumab Biosimilar Available In Pre-Filled Syringe

FORMYCON AG :EQS-NEWS: FORMYCON’S FYB201/RANIVISIO® SETS INNOVATIVE STANDARD AS EUROPE’S FIRST RANIBIZUMAB BIOSIMILAR AVAILABLE IN PRE-FILLED SYRINGEFORMYCON AG - TEVA PHARMACEUTICAL INDUSTRIES LTD. TO COMMERCIALIZE FYB201/RANIVISIO®2 PFS ACROSS EUROPE

Reuters·
DE
FYB
0.00%
Reuters·
DE
FYB
0.00%

Formycon AG announces licensing agreements for Eylea biosimilar FYB203 commercialization in Australia and Latin America

Formycon AG has announced that Klinge Biopharma GmbH has signed exclusive licensing agreements with Actor Pharmaceuticals for Australia and Megalabs S.A. for Latin America regarding the commercialization of Formycon’s Eylea® biosimilar FYB203. Klinge will receive upfront and milestone payments, along with royalties on net sales, while Formycon will manage the supply chain and receive additional service payments. This strategic move enhances Formycon's market presence in these regions.

Reuters·
DE
FYB
0.00%
Reuters·
DE
FYB
0.00%